As such, CDC25 phosphatases are some of the more attractive targets for cancer therapy, especially for cancer types that are more aggressive and more difficult to treat such as receptor protein triple-negative breast cancer (He et al., 2013; Liu et al., 2018). The gene discussed is CDC25C; the disease is cancer.